Treatment of diffuse transitional cell carcinoma in situ by whole bladder hematoporphyrin derivative photodynamic therapy.
A total of 10 patients with diffuse, resistant transitional cell carcinoma of the bladder underwent whole bladder hematoporphyrin derivative photodynamic therapy in which a new light bulb fiber was used to deliver red light (630 nm.) from an argon pumped dye laser. Six patients who had carcinoma in situ alone had a complete response, 2 with diffuse carcinoma in situ and stage Ta lesions had persistent stage Ta disease and 2 with diffuse carcinoma in situ and focal stage T2 disease had disappearance of the carcinoma in situ but persistent invasive disease at 3 months. This new light delivery system appears to be effective in the treatment of diffuse, resistant carcinoma in situ of the bladder.
Benson
R C
RC
D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000532:radiotherapy*; D005260:Female; D017324:Hematoporphyrin Derivative; D006415:Hematoporphyrins / Q000627:therapeutic use*; D006801:Humans; D053685:Laser Therapy; D008297:Male; D008875:Middle Aged; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000532:radiotherapy*
D006415:Hematoporphyrins; D011838:Radiation-Sensitizing Agents; D017324:Hematoporphyrin Derivative